Influence of Antenatal Glucocorticosteroid Exposure on Osteoprotegerin and Receptor Activator of Nuclear Factor κB Ligand Levels in Newborn Infants

被引:2
作者
Karatza, Ageliki A. [1 ]
Fouzas, Sotirios [1 ]
Giannakopoulos, Ioannis [1 ]
Kritikou, Dimitra [1 ,2 ]
Chrysis, Dionisios [1 ,2 ]
机构
[1] Univ Patras, Sch Med, Dept Paediat, GR-26110 Patras, Greece
[2] Univ Patras, Sch Med, Dept Paediat Endocrinol, GR-26110 Patras, Greece
来源
HORMONE RESEARCH IN PAEDIATRICS | 2016年 / 85卷 / 04期
关键词
Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand; Antenatal corticosteroids; Neonates; SERUM OSTEOPROTEGERIN; VASCULAR CALCIFICATION; BONE; RANKL; AGE; OSTEOCLASTOGENESIS; PREGNANCY; CHILDREN; THERAPY; EXCESS;
D O I
10.1159/000444638
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aims: The physiologic relevance of osteoprotegerin (OPG) and the receptor activator of nuclear factor kappa B ligand (RANKL) in the preterm neonate is unknown. The aim of this study was to examine the effects of prematurity on OPG and RANKL concentrations at birth and to investigate in particular whether antenatal corticosteroid (ACS) exposure affects serum OPG and RANKL levels in premature neonates. Methods: Quantitative determination (enzyme immunoassay) of serum OPG and RANKL at 24 postnatal hours was performed in 47 healthy term neonates, 43 preterm newborns not exposed to ACS, and 55 preterm infants exposed to ACS. Results: OPG in the ACS-exposed preterm group (median 5.13 pmol/l, range 1.62-15.12) was significantly higher compared to preterm neonates not exposed to ACS (median 4.52 pmol/l, range 0.86-8.98, p < 0.05) and to unexposed term neonates (median 4.47 pmol/l, range 2.70-10.72, p < 0.05). Conversely, there was no difference in RANKL levels between the study groups. OPG and RANKL values were also similar between term and preterm neonates not exposed to ACS. Conclusions: Preterm neonates exposed to ACS have higher serum levels of OPG, while premature neonates not exposed to ACS have serum OPG and RANKL levels similar to those measured in healthy term neonates. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:257 / 264
页数:8
相关论文
共 40 条
[1]   Review of the Antenatal and Postnatal Use of Steroids [J].
Bartholomew, Julie ;
Kovacs, Lajos ;
Papageorgiou, Apostolos .
INDIAN JOURNAL OF PEDIATRICS, 2014, 81 (05) :466-472
[2]   Placental transport: a function of permeability and perfusion [J].
Battaglia, Frederick C. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (02) :591S-597S
[3]   RANKL, RANK, osteoprotegerin:: key partners of osteoimmunology and vascular diseases [J].
Baud'huin, M. ;
Lamoureuxa, F. ;
Duplomba, L. ;
Redini, F. ;
Heymann, D. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (18) :2334-2350
[4]   GLUCOCORTICOID EXPOSURE INUTERO - NEW MODEL FOR ADULT HYPERTENSION [J].
BENEDIKTSSON, R ;
LINDSAY, RS ;
NOBLE, J ;
SECKL, JR ;
EDWARDS, CRW .
LANCET, 1993, 341 (8841) :339-341
[5]   Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice [J].
Bennett, Brian J. ;
Scatena, Marta ;
Kirk, Elizabeth A. ;
Rattazzi, Marcello ;
Varon, Rebecca M. ;
Averill, Michelle ;
Schwartz, Stephen M. ;
Giachelli, Cecilia M. ;
Rosenfeld, Michael E. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (09) :2117-2124
[6]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[7]   Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis [J].
Buzi, F ;
Maccarinelli, G ;
Guaragni, B ;
Ruggeri, F ;
Radetti, G ;
Meini, A ;
Mazzolari, E ;
Cocchi, D .
CLINICAL ENDOCRINOLOGY, 2004, 60 (01) :87-91
[8]   Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin [J].
Collin-Osdoby, P .
CIRCULATION RESEARCH, 2004, 95 (11) :1046-1057
[9]   Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randornised controlled trial [J].
Dalziel, SR ;
Walker, NK ;
Parag, V ;
Martell, C ;
Rea, HH ;
Rodgers, A ;
Harding, JE .
LANCET, 2005, 365 (9474) :1856-1862
[10]   Cardiovascular follow-up at school age after perinatal glucocorticoid exposure in prematurely born children - Perinatal glucocorticoid therapy and cardiovascular follow-up [J].
de Vries, Willem B. ;
Karemaker, Rosa ;
Mooy, Nicole F. ;
Strengers, Jan L. M. ;
Kemperman, Hans ;
Baerts, Wim ;
Veen, Sylvia ;
Visser, Gerard H. A. ;
Heijnen, Cobi J. ;
van Bel, Frank .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2008, 162 (08) :738-744